ALKS
Price
$29.05
Change
+$0.79 (+2.80%)
Updated
Aug 15 closing price
Capitalization
4.8B
66 days until earnings call
INDV
Price
$23.46
Change
+$0.29 (+1.25%)
Updated
Aug 15 closing price
Capitalization
2.93B
67 days until earnings call
Interact to see
Advertisement

ALKS vs INDV

Header iconALKS vs INDV Comparison
Open Charts ALKS vs INDVBanner chart's image
Alkermes
Price$29.05
Change+$0.79 (+2.80%)
Volume$1.59M
Capitalization4.8B
Indivior
Price$23.46
Change+$0.29 (+1.25%)
Volume$1.56M
Capitalization2.93B
ALKS vs INDV Comparison Chart in %
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INDV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. INDV commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and INDV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (ALKS: $29.05 vs. INDV: $23.46)
Brand notoriety: ALKS and INDV are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 84% vs. INDV: 52%
Market capitalization -- ALKS: $4.8B vs. INDV: $2.93B
ALKS [@Pharmaceuticals: Generic] is valued at $4.8B. INDV’s [@Pharmaceuticals: Generic] market capitalization is $2.93B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green whileINDV’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • INDV’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than INDV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 5 TA indicator(s) are bullish while INDV’s TA Score has 3 bullish TA indicator(s).

  • ALKS’s TA Score: 5 bullish, 5 bearish.
  • INDV’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ALKS is a better buy in the short-term than INDV.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а +8.76% price change this week, while INDV (@Pharmaceuticals: Generic) price change was +6.64% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 22, 2025.

INDV is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.8B) has a higher market cap than INDV($2.93B). INDV has higher P/E ratio than ALKS: INDV (28.96) vs ALKS (14.03). INDV YTD gains are higher at: 88.737 vs. ALKS (1.008). ALKS has higher annual earnings (EBITDA): 450M vs. INDV (261M). ALKS has more cash in the bank: 1.02B vs. INDV (510M). ALKS has less debt than INDV: ALKS (72.7M) vs INDV (366M). ALKS has higher revenues than INDV: ALKS (1.51B) vs INDV (1.17B).
ALKSINDVALKS / INDV
Capitalization4.8B2.93B164%
EBITDA450M261M172%
Gain YTD1.00888.7371%
P/E Ratio14.0328.9648%
Revenue1.51B1.17B128%
Total Cash1.02B510M199%
Total Debt72.7M366M20%
FUNDAMENTALS RATINGS
ALKS vs INDV: Fundamental Ratings
ALKS
INDV
OUTLOOK RATING
1..100
1830
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
4145
SMR RATING
1..100
4077
PRICE GROWTH RATING
1..100
6235
P/E GROWTH RATING
1..100
30100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INDV's Valuation (94) in the null industry is in the same range as ALKS (97) in the Biotechnology industry. This means that INDV’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (41) in the Biotechnology industry is in the same range as INDV (45) in the null industry. This means that ALKS’s stock grew similarly to INDV’s over the last 12 months.

ALKS's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for INDV (77) in the null industry. This means that ALKS’s stock grew somewhat faster than INDV’s over the last 12 months.

INDV's Price Growth Rating (35) in the null industry is in the same range as ALKS (62) in the Biotechnology industry. This means that INDV’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's P/E Growth Rating (30) in the Biotechnology industry is significantly better than the same rating for INDV (100) in the null industry. This means that ALKS’s stock grew significantly faster than INDV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSINDV
RSI
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
66%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 3 days ago
64%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
N/A
MACD
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 5 days ago
75%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 12 days ago
63%
Bearish Trend 28 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
66%
Aroon
ODDS (%)
Bearish Trend 3 days ago
58%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INDV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIQEX75.700.08
+0.11%
Fidelity Advisor Canada Z
USPFX33.430.01
+0.03%
Union Street Partners Value Advisor
FFBGX40.45-0.01
-0.02%
American Funds Global Balanced 529-F-3
JVTIX86.81-0.06
-0.07%
Janus Henderson Venture I
ARSMX9.85-0.07
-0.71%
AMG River Road Small-Mid Cap Value N

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with COLL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then COLL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+2.80%
COLL - ALKS
37%
Loosely correlated
+1.56%
AMRX - ALKS
37%
Loosely correlated
+0.64%
PAHC - ALKS
33%
Loosely correlated
+0.33%
PRGO - ALKS
33%
Poorly correlated
-1.43%
VTRS - ALKS
32%
Poorly correlated
-0.75%
More

INDV and

Correlation & Price change

A.I.dvisor tells us that INDV and ALKS have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INDV and ALKS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INDV
1D Price
Change %
INDV100%
+1.25%
ALKS - INDV
25%
Poorly correlated
+2.80%
HROW - INDV
24%
Poorly correlated
-2.97%
VTRS - INDV
23%
Poorly correlated
-0.75%
COLL - INDV
23%
Poorly correlated
+1.56%
AMRX - INDV
23%
Poorly correlated
+0.64%
More